



Abbott Laboratories (Pakistan) Limited
 City Office: 8th Floor Faysal House
 ST-02, Shahr-e-Faisal, Karachi-75350
 P.O. Box 7229 Karachi 74400
 Tel : (92-21) 111-Abbott (111-222-688)
 : (92-21) 32799018-19
 Fax : (92-21) 32800244

Abbott Laboratories (Pakistan) Limited
 Registered Office: Opp. Radio Pakistan
 Transmission Centre, Hyderabad Road,
 Landhi, Karachi-75120
 P.O. Box 7229, Karachi 74400
 Tel : (92-21) 35069748-49
 Fax : (92-21) 35001903

October 23rd, 2023

The General Manager
 Pakistan Stock Exchange Limited
 Stock Exchange Building
 Stock Exchange Road
 Karachi

Sub: Financial Results for the Nine months and Quarter ended September 30th, 2023

Dear Sir,

We have to inform you that the Board of Directors' of our company in their meeting held on Monday, October 23rd, 2023 at 11:00 a.m at Abbott Laboratories (Pakistan) Limited, 8th Floor, Faysal House, Shahr-e-Faisal, Karachi, considered and approved the financial results of the Company as follows:

	<u>Nine Months Ended</u>		<u>Quarter Ended</u>	
	September 30, 2023	September 30, 2022	September 30, 2023	September 30, 2022
	----- (Rupees in ' 000) -----			
SALES- NET				
Local	39,362,460	35,269,498	13,542,120	11,553,166
Export	1,862,626	1,681,939	439,788	717,842
	<u>41,225,086</u>	<u>36,951,437</u>	<u>13,981,908</u>	<u>12,271,008</u>
Cost of sales	(32,910,279)	(24,849,827)	(11,472,137)	(8,630,742)
GROSS PROFIT	<u>8,314,807</u>	<u>12,101,610</u>	<u>2,509,771</u>	<u>3,640,266</u>
Selling and distribution expenses	(6,191,729)	(5,450,405)	(2,066,577)	(1,839,051)
Administrative expenses	(771,683)	(657,004)	(257,801)	(234,927)
Other charges	(1,592,953)	(1,353,027)	(20,068)	(559,368)
Other income	1,235,286	758,928	171,533	283,796
	<u>(7,321,079)</u>	<u>(6,701,508)</u>	<u>(2,172,913)</u>	<u>(2,349,550)</u>
Finance costs	993,728	5,400,102	336,858	1,290,716
	<u>(24,019)</u>	<u>(37,881)</u>	<u>(7,092)</u>	<u>(9,760)</u>
PROFIT BEFORE TAXATION	969,709	5,362,221	329,766	1,280,956
Taxation				
Current	(1,339,300)	(1,764,428)	(254,507)	(458,053)
Prior	(340,421)	(832,274)	15,789	8,988
Deferred	(82,684)	(200,536)	(84,377)	(46,921)
	<u>(1,762,405)</u>	<u>(2,797,238)</u>	<u>(323,095)</u>	<u>(495,986)</u>
NET (LOSS) / PROFIT FOR THE PERIOD	<u>(792,696)</u>	<u>2,564,983</u>	<u>6,671</u>	<u>784,970</u>
BASIC AND DILUTED (LOSS) / EARNINGS PER SHARE (Rs. per share)	<u>(8.10)</u>	<u>26.20</u>	<u>0.07</u>	<u>8.02</u>



The Quarterly Report of the Company for the period ended September 30, 2023 will be transmitted through PUCARS separately, within the specified time.

Yours faithfully,
ABBOTT LABORATORIES (PAKISTAN) LIMITED

SYED ANIS AHMED
CHIEF EXECUTIVE &
MANAGING DIRECTOR